1. EU regulator reviews Valneva's chikungunya vaccine due to adverse events. 2. Two deaths reported in older adults after vaccination may affect market sentiment.
Adverse events and fatalities can compromise vaccine credibility, impacting Valneva's stock and related firms. Historical incidents, such as with AstraZeneca's vaccine, show that negative news can lead to significant stock declines.
The article could significantly impact investor confidence in health sector stocks, including INRLF, given its ties to vaccine developments. Stakeholders will closely monitor regulatory outcomes and safety evaluations.
News of adverse effects typically leads to immediate market reactions, particularly in biotech stocks. As regulatory reviews often generate quick sentiment shifts, market response is likely to be swift.